Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptors

Archiv der Pharmazie

Volumn 344, Issue 1, 2011, Pages 28-36

  Robaa, Dina ^a   Kretschmer, Robert ^a   Siol, Oliver ^a   Abulazm, Shams Eldin ^b   Elkhawass, Elsayeda ^b   Lehmann, Jochen ^a,c   Enzensperger, Christoph ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Alexandria University Faculty of Pharmacy   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

azecines; dopamine receptors; indole NH; SAR

Indexed keywords

14 (2 FLUOROETHYL) 7 METHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE; 14 (CYCLOPROPYLMETHYL) 7 METHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE; 14 ACETYL 7 METHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE; 14 ALLYL 7 METHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F] [3]BENZAZECINE; 14 ETHYL 7 METHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO [3,2 F][3]BENZAZECINE; 7 METHYL 14 (3-PHENYLPROPYL) 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE; 7 METHYL 14 OCTYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO [3,2 F][3]BENZAZECINE; 7 METHYL 14 PENTYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE; 7 METHYL 14 PROP 2 YNYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE HYDROCHLORIDE; 7 METHYL 14 PROPYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3]BENZAZECINE; 7 METHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3] BENZAZECINE; 7,14 DIMETHYL 6,7,8,9,14,15 HEXAHYDRO 5H INDOLO[3,2 F][3] BENZAZECINE; AZECINE; CALCIUM; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; INDOLE; QUINAZOLINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CYTOTOXICITY; DRUG BINDING; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; RADIOASSAY; STRUCTURE ACTIVITY RELATION;

DOPAMINE ANTAGONISTS; HUMANS; INDOLES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78651309431     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201000121     Document Type: Article

References (15)

1. G. Emilien, J. M. Maloteaux, M. Geurts, K. Hoogenberg, S. Cragg, Pharmacol. Ther. 1999, 84, 133-156.
2. M. Decker, K. J. Schleifer, M. Nieger, J. Lehmann, Eur. J. Med. Chem. 2004, 39, 481-489.
3. B. Hoefgen, M. Decker, P. Mohr, A. M. Schramm, S. A. F. Rostom, H. El Subbagh, P. M. Schweikert, D. R. Rudolf, M. U. Kassack, J. Lehmann, J. Med. Chem. 2006, 49, 760-769.
4. T. Witt, F. J. Hock, J. Lehmann, J. Med. Chem. 2000, 43, 2079-2081.
5. C. Enzensperger, S. Kilian, M. Ackermann, A. Koch, K. Kelch, J. Lehmann, Bioorg. Med. Chem. Lett. 2007, 17, 1399-1402.
6. D. Robaa, C. Enzensperger, S. D. Abul Azm, E. S. El Khawass, O. El Sayed, J. Lehmann, J. Med. Chem. 2010, 53, 2646-2650.
7. J. Lehmann, M. Nieger, T. Witt, Heterocycles 1994, 38, 511-528.
8. R. J. Bushby, Q. Rev. Chem. Soc. 1970, 24, 585-600.
9. M. Decker, J. Lehmann, Arch. Pharm. 2003, 336, 466-476.
10. M. U. Kassack, B. Hoefgen, J. Lehmann, N. Eckstein, J. M. Quillan, W. Sadee, J. Biomol. Screen. 2002, 7, 233-246.
11. F. Gaube, S. Wolfl, L. Pusch, U. Werner, T. C. Kroll, D. Schrenk, R. W. Hartmann, M. Hamburger, Planta Medica 2008, 74, 1701-1708.
12. G. Giorgioni, A. Piergentili, S. Ruggieri, W. Quaglia, Mini Rev. Med. Chem. 2008, 8, 976-995.
13. I. W. Elliott, Y. G. Bryant, J. Het. Chem. 1967, 4, 127-129.
14. Y. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.
15. T. H. Rasmussen, J. B. Nielsen, Biomarkers 2002, 7, 322-336.